- Trials with a EudraCT protocol (18)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
18 result(s) found for: Isotypes.
Displaying page 1 of 1.
EudraCT Number: 2021-003804-42 | Sponsor Protocol Number: INCENTIVE-QIV2-EU | Start Date*: 2021-10-04 |
Sponsor Name:Helse Bergen HF | ||
Full Title: Immunogenicity, molecular profiling and safety of a marketed quadrivalent influenza vaccine (Vaxigrip Tetra) administered by the intramuscular route in children 3-11 years old | ||
Medical condition: Immune response to infuenza vaccine in young children | ||
Disease: | ||
Population Age: Children, Under 18 | Gender: Male, Female | |
Trial protocol: NO (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2016-002256-25 | Sponsor Protocol Number: HYPATIA | Start Date*: 2018-03-09 | |||||||||||
Sponsor Name:Guy's and St Thomas' NHS Foundation Trust | |||||||||||||
Full Title: HYPATIA: A prospective randomised controlled trial of HYdroxychloroquine to improve Pregnancy outcome in women with AnTIphospholipid Antibodies | |||||||||||||
Medical condition: Pregnant women with antiphospholipid antibodies | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DK (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-003038-26 | Sponsor Protocol Number: ARGX-113-1603 | Start Date*: 2017-02-08 | |||||||||||
Sponsor Name:Argenx BVBA | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled, Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients with Primary Immune Thrombocytopenia, followed by an Op... | |||||||||||||
Medical condition: Primary Immune Thrombocytopenia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) HU (Completed) CZ (Completed) BE (Completed) DE (Completed) AT (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-001205-16 | Sponsor Protocol Number: 54767414SMM3001 | Start Date*: 2017-10-18 | |||||||||||
Sponsor Name:Janssen-Cilag International N.V. | |||||||||||||
Full Title: A Phase 3 Randomized, Multicenter Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects with High-risk Smoldering Multiple Myeloma | |||||||||||||
Medical condition: Smoldering multiple myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Trial now transitioned) SE (Trial now transitioned) NL (Trial now transitioned) GB (GB - no longer in EU/EEA) DE (Trial now transitioned) HU (Trial now transitioned) ES (Ongoing) NO (Trial now transitioned) CZ (Trial now transitioned) DK (Trial now transitioned) GR (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-001973-42 | Sponsor Protocol Number: 109MS310 | Start Date*: 2015-12-17 | |||||||||||
Sponsor Name:Biogen Idec Research Limited | |||||||||||||
Full Title: An Open-Label Study to Assess the Effects of BG00012 on Lymphocyte Subsets in Subjects With Relapsing-Remitting Multiple Sclerosis | |||||||||||||
Medical condition: Relapsing Remitting Multiple Sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) LT (Completed) PL (Completed) BG (Completed) HR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-004486-33 | Sponsor Protocol Number: BTT-gpASIT006 | Start Date*: 2011-11-22 | |||||||||||
Sponsor Name:BioTech Tools S.A. | |||||||||||||
Full Title: Safety, clinical tolerability and immunogenicity of gpASIT+TM administered subcutaneously to hay fever patients either alone or in presence of DnaK immunoregulating adjuvant. | |||||||||||||
Medical condition: Treatment of seasonal grass pollen rhinoconjunctivitis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-000145-12 | Sponsor Protocol Number: 5997 | Start Date*: 2012-08-15 | |||||||||||
Sponsor Name:The Newcastle upon Tyne Hospitals NHS Foundation Trust | |||||||||||||
Full Title: Rituximab for the Treatment of Fatigue in Primary Biliary Cirrhosis (PBC) | |||||||||||||
Medical condition: Severe fatigue in Primary Biliary Cirrhosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-003755-64 | Sponsor Protocol Number: DiAPREV/2014 | Start Date*: 2014-11-13 |
Sponsor Name:Helena Elding Larsson | ||
Full Title: A double-blind, randomized investigator-initiated study to determine the safety and the effect of Diamyd® in combination with Vitamin D on the progression to type 1 diabetes in children with multip... | ||
Medical condition: Children with HLA risk and persistent islet autoantibody positivity which is associated with a defined risk for type 1 diabetes | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: View results |
EudraCT Number: 2015-005202-10 | Sponsor Protocol Number: IEO388 | Start Date*: 2016-07-06 | ||||||||||||||||
Sponsor Name:ISTITUTO EUROPEO DI ONCOLOGIA | ||||||||||||||||||
Full Title: An open label, single-center, not controlled, exploratory study to develop and evaluate the application of a new technique of radioguided surgery in gastro-entero-pancreatic neuroendocrine tumors (... | ||||||||||||||||||
Medical condition: Gastro-entero-pancreatic neuroendocrine tumors | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-002872-14 | Sponsor Protocol Number: VAC079 | Start Date*: 2019-11-12 | |||||||||||
Sponsor Name:University of Oxford / Clinical Trials and Research Governance | |||||||||||||
Full Title: A Phase I/IIa clinical trial to assess the safety, immunogenicity and efficacy of the blood-stage Plasmodium vivax malaria vaccine candidate PvDBPII in Matrix M1 in healthy adults living in the UK | |||||||||||||
Medical condition: Plasmodium vivax malaria | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-000643-27 | Sponsor Protocol Number: VAC071 | Start Date*: 2019-09-23 | |||||||||||
Sponsor Name:University of Oxford / Clinical Trials and Research Governance | |||||||||||||
Full Title: A Phase IIa challenge study to assess efficacy of the Plasmodium vivax malaria vaccine candidates ChAd63 PvDBP and MVA PvDBP in healthy adults living in the UK | |||||||||||||
Medical condition: Plasmodium vivax malaria | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-001861-25 | Sponsor Protocol Number: DIAGNODE-2(D/P2/17/6) | Start Date*: 2017-06-22 | |||||||||||
Sponsor Name:Diamyd Medical AB | |||||||||||||
Full Title: A Phase IIb, 2-Arm, Randomized, Double-blind, Placebo-Controlled, Multicentre Study to Optimize Diamyd® Therapy Administered into Lymph Nodes Combined with Oral Vitamin D to Investigate the Impact ... | |||||||||||||
Medical condition: Type 1 diabetes | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) CZ (Completed) ES (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-001115-73 | Sponsor Protocol Number: Regenerate-1 | Start Date*: 2018-06-05 | |||||||||||
Sponsor Name:Uppsala University Hospital | |||||||||||||
Full Title: A Phase I/II, 2-Arm, Open Label, Single Centre Study to Investigate the Safety and Effect of Oral GABA Therapy on β-cell Regeneration in Type 1-diabetes Patients | |||||||||||||
Medical condition: Type 1 diabetes | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-001027-12 | Sponsor Protocol Number: IsKPd-IFM2018-03 | Start Date*: 2019-10-07 | |||||||||||
Sponsor Name:CHU de Poitiers | |||||||||||||
Full Title: Multicenter Open label Phase 2 study of Isatuximab plus Pomalidomide and Dexamethasone with Carfilzomib in Relapsed or Refractory Multiple Myeloma | |||||||||||||
Medical condition: | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000006-16 | Sponsor Protocol Number: APHP201098 | Start Date*: 2022-01-10 | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | |||||||||||||
Full Title: A phase 3 randomized and double-blind controlled trial comparing the efficacy and safety of subcutaneous belimumab or placebo in addition to rituximab in adult patients with persistent or chronic i... | |||||||||||||
Medical condition: Adults with a definite diagnosis of primary chronic immune thrombocytopeniaaccording to the standard definition. Patients with antinuclear antibodies with no definite criteria for systemic lupus wi... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-003656-35 | Sponsor Protocol Number: E7389-G000-211 | Start Date*: 2006-03-14 |
Sponsor Name:Eisai Limited | ||
Full Title: A phase II open label single-arm study of E7389 in patients with locally advanced or metastatic breast cancer, previously treated with anthracycline, taxane, and capecitabine therapy, refractory to... | ||
Medical condition: Locally advanced or metastatic breast cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: BE (Completed) ES (Completed) GB (Completed) AT (Completed) DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-004271-37 | Sponsor Protocol Number: E7389-G000-204 | Start Date*: 2006-01-20 | |||||||||||
Sponsor Name:Eisai Limited | |||||||||||||
Full Title: A Phase II Multicenter, Open Label, Two-Stage Design Study Evaluating E7389 in Patients with Hormone Refractory Prostate Cancer with Advanced and/or Metastatic Disease Stratified by Prior Chemother... | |||||||||||||
Medical condition: Advanced/metastatic hormone-refractory prostate cancer. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: GB (Completed) ES (Completed) HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-002101-21 | Sponsor Protocol Number: ARGX-113-1803 | Start Date*: 2020-05-25 | |||||||||||
Sponsor Name:argenx BV | |||||||||||||
Full Title: A Phase 3, Multicenter, Open-label, Long-term Trial to Evaluate the Safety and Efficacy of Efgartigimod (ARGX-113) 10 mg/kg Intravenous in Adult Patients With Primary Immune Thrombocytopenia | |||||||||||||
Medical condition: Primary immune thrombocytopenia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) ES (Completed) HU (Trial now transitioned) FR (Completed) BE (Completed) CZ (Trial now transitioned) BG (Completed) DE (Completed) GB (GB - no longer in EU/EEA) AT (Completed) IT (Trial now transitioned) PL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
